Open AccessSTUDY OF BIOCHEMICAL MARKERS IN ARTHRITIS PATIENTS
Author(s) -
Yogesh Shivmurti Khandalkar,
Vishal Supada Patil,
Ketan Ajay Kulkarni,
Harsh Arunkumar Raithatha
Publication year - 2022
Publication title -
international journal of medical and biomedical studies
Language(s) - English
Resource type - Journals
eISSN - 2589-8698
pISSN - 2589-868X
DOI - 10.32553/ijmbs.v6i2.2450
Subject(s) - medicine , arthritis , osteoarthritis , rheumatoid arthritis , overweight , physical therapy , orthopedic surgery , rheumatology , surgery , obesity , pathology , alternative medicine
The most prevalent kind of arthritis is osteoarthritis. It happens when joints are overworked and most commonly affects the elderly, although it can also affect persons who have had joint injuries or who are overweight. The weight-bearing joints, such as the knees, hips, foot, and spine, are the ones most prone to osteoporosis. It's a loss of cartilage that leads to inflammation and unpleasant motions.Arthritis is a disease that causes one or more joints to swell and become tender. The most typical symptoms of arthritis are joint pain and stiffness, which usually worsen with age.
Aim: Study of Biochemical Markers in Arthritis Patients
Material and Method: The study included 40 patients, 20 men and 20 females, ranging in age from 25 to 50 years old from Central India. All of the people in the study were healthy, with no congenital anomalies, inflammation, trauma, or orthopedic treatment.
Result: comparison between Arthritis female and Arthritismale subject’s serum Anti CCP value are raised in Arthritis female subjects compare to male subjects the data show that statistically significant p-valve are P < 0.01.
Conclusion: In Arthritis patients, Anti-CCP has become a key serologic marker. It can be utilized as a test for early identification of RA, differential diagnosis between RA and ASO other rheumatic or immunological disorders, prognosis prediction, and therapy outcome evaluation.
Keywords: Anti-CCP, Arthritis, Osteoarthritis, subchondral, ASO